C4 Therapeutics, Inc. (CCCC)
Develops drugs that destroy disease-causing proteins to treat cancer and neurological disorders.
$3.52-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+66.0%
The outlook
CCCC trades at $3.52, sitting roughly midway in its 52-week range with mixed price momentum. Analyst coverage leans bullish, with an average price target implying substantial upside from current levels. The stock shows mixed signals against its moving averages, reflecting uncertainty in near-term direction.
What’s behind the score
Price trendMixed vs its moving averages
52-week range53% of the way from its 52-week low to high
Price targetAvg target +279% vs current price
Analyst price target
~12-month · 6 analysts$13.33average target+278.8% vs now
Now $3.52
Low $7.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$389.2M
52-wk high
$5.17
52-wk low
$1.69
50-day avg
$3.90
200-day avg
$2.83
Trailing P/E
—